Salt Lake City April 8 2009 -- Myriad Pharmaceuticals Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor MPC-3100 for the treatment of cancer. The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase 1 trial will assess the safety and pharmacokinetics profile of MPC-3100.

 Idiopathic thrombocytopenic purpura (ITP) is a condition which creates a short supply of blood cells called platelets. This condition is also acknowledged as immune thrombocytopenic purpura or immune-mediated thrombocytopenic purpura. Since the advent of platelet transfusions purpura (bruises) are no longer a prominent component of the disease though serious bleeding may occur.  If the platelet count is below 20 000 ITP patients can experience bruising petechiae nosebleeds and bleeding gums. The cause of the illness is an immune system reaction against normal platelets.

Lymphoma is a malignant neoplasm of the immune system and lymph nodes. Men and women aged 50 and above are more likely to develop this disease. With the increase in the frequency of non-Hodgkin’s lymphoma (NHL) during the past decade approximately 50 000 American people are suffering from this illness now. The exact cause of the disease is still unknown but certain viruses like EBV or HIV are responsible for some lymphomas.

ESC 08-Munich Germany: The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study failed to show that PCI is non inferior to CABG treatment in patients with left main or 3-vessel coronary artery disease. The findings were presented by Dr. Friedrich Mohr of Germany and Dr. Patrick Serruys of the Netherlands at the European Society of Cardiology Congress 2008 in Munich.